WaveMan
WaveMan · Company
ACOG · Alpha Cognition Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ACOG Alpha Cognition (ACOG) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001655923
Quote by TradingView
Cluster · 3 insidersC-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
8
13F, latest reported quarter

What the filings say about ACOG

Insiders, 180 days
+$6.2M net bought
3 buyers

Alpha Cognition insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Alpha Cognition Inc. insiders bought a net $6.2M of stock across 66 Form 4 purchases and sales, with 3 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Opaleye Management Inc.
BUY
2026-10-26 SECtraded 2026-10-23
14,973
$123.3K
n/a
Context
  • 57 earlier Form 4 trades (code P or S) here by this insider (57 buys), the last on Oct 22, 2026.
  • +48.6% median (+42.9% mean) 90-day return after 19 previous buys.
  • The trade is 0.5% of the 3,291,984 shares held after it.
  • No other insider bought within 30 days.
  • 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Opaleye Management Inc. bought about $123.3K of ACOG on Oct 23, 2026; 8 funds added in the latest 13F quarter.
Opaleye Management Inc.
BUY
2026-10-26 SECtraded 2026-10-22
17,117
$142.5K
n/a
Context
  • 56 earlier Form 4 trades (code P or S) here by this insider (56 buys), the last on Oct 16, 2026.
  • +47.1% median (+42.2% mean) 90-day return after 20 previous buys.
  • The trade is 0.5% of the 3,277,011 shares held after it.
  • No other insider bought within 30 days.
  • 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Opaleye Management Inc. bought about $142.5K of ACOG on Oct 22, 2026; 8 funds added in the latest 13F quarter.
Opaleye Management Inc.
BUY
2026-10-19 SECtraded 2026-10-16
14,283
$117.6K
-3.6%
Context
  • 55 earlier Form 4 trades (code P or S) here by this insider (55 buys), the last on Oct 15, 2026.
  • +45.6% median (+41.3% mean) 90-day return after 21 previous buys.
  • The trade is 0.4% of the 3,259,894 shares held after it.
  • No other insider bought within 30 days.
  • 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Opaleye Management Inc. bought about $117.6K of ACOG on Oct 16, 2026; 8 funds added in the latest 13F quarter.
Opaleye Management Inc.
BUY
2026-10-19 SECtraded 2026-10-15
22,657
$191.0K
-3.6%
Context
  • 54 earlier Form 4 trades (code P or S) here by this insider (54 buys), the last on Oct 1, 2026.
  • +45.5% median (+40.5% mean) 90-day return after 22 previous buys.
  • The trade is 0.7% of the 3,245,611 shares held after it.
  • No other insider bought within 30 days.
  • 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Opaleye Management Inc. bought about $191.0K of ACOG on Oct 15, 2026; 8 funds added in the latest 13F quarter.
Opaleye Management Inc.
BUY
2026-10-02 SECtraded 2026-10-01
19,050
$165.6K
-9.3%
Context
  • 53 earlier Form 4 trades (code P or S) here by this insider (53 buys), the last on Sep 25, 2026.
  • +45.4% median (+39.6% mean) 90-day return after 23 previous buys.
  • The trade is 0.6% of the 3,222,954 shares held after it.
  • No other insider bought within 30 days.
  • 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Opaleye Management Inc. bought about $165.6K of ACOG on Oct 1, 2026; 8 funds added in the latest 13F quarter.
66 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 61 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$6.2M over 180 days
+$2.6M over 90 days · +$6.1M of it by a 10%+ holder
more than 94% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
8 funds bought in last quarter
below 89% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
-202.2% net margin
below 65% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
3.0% of the float short (float per yahoo 2026-10-26) · 2.8 days to cover · settled 2026-09-30
below 69% of Pharma & Biotech
What changed in the last 30 days
Oct 26Insider Opaleye Management Inc. bought $1.0M (7 trades, Sep 24 to Oct 23)

Watch ACOG

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+20.3%12M
-35%-9%+16%+41%2025-102025-122026-022026-042026-062026-082026-10 2026-07-22 · Opaleye Management Inc. bought $1.1M2026-06-26 · Opaleye Management Inc. bought $975.0K2026-02-23 · Opaleye Management Inc. bought $564.4K2026-09-16 · Opaleye Management Inc. bought $454.6K2026-05-29 · Opaleye Management Inc. bought $416.4K2026-08-03 · Opaleye Management Inc. bought $400.0K2026-07-23 · Opaleye Management Inc. bought $388.6K2026-09-14 · Opaleye Management Inc. bought $351.1K2026-02-24 · Opaleye Management Inc. bought $310.8K2026-03-03 · Opaleye Management Inc. bought $266.9K2026-03-05 · Opaleye Management Inc. bought $243.7K2026-09-16 · Opaleye Management Inc. bought $228.0K2026-10-15 · Opaleye Management Inc. bought $191.0K2026-10-01 · Opaleye Management Inc. bought $165.6K2026-09-24 · Opaleye Management Inc. bought $157.1K2026-06-09 · Opaleye Management Inc. bought $148.6K2026-10-22 · Opaleye Management Inc. bought $142.5K2026-10-23 · Opaleye Management Inc. bought $123.3K2026-10-16 · Opaleye Management Inc. bought $117.6K2026-03-02 · Opaleye Management Inc. bought $116.0K2026-03-04 · Opaleye Management Inc. bought $115.0K2026-09-25 · Opaleye Management Inc. bought $113.7K2026-05-18 · Opaleye Management Inc. bought $99.0K2026-05-15 · Opaleye Management Inc. bought $97.1K2026-08-21 · Wills Robert James bought $96.2K2026-05-21 · Opaleye Management Inc. bought $90.9K2026-07-22 · Opaleye Management Inc. bought $78.3K2026-06-05 · Opaleye Management Inc. bought $58.6K2026-02-20 · Opaleye Management Inc. bought $58.4K2026-03-27 · Opaleye Management Inc. bought $50.8K2026-05-20 · Opaleye Management Inc. bought $49.7K2026-03-25 · Opaleye Management Inc. bought $46.6K2026-03-13 · Opaleye Management Inc. bought $42.3K2026-03-26 · Opaleye Management Inc. bought $38.6K2026-06-10 · Opaleye Management Inc. bought $35.2K2026-03-12 · Opaleye Management Inc. bought $33.4K2026-02-24 · Opaleye Management Inc. bought $29.0K2026-03-05 · Opaleye Management Inc. bought $29.0K2026-09-15 · Opaleye Management Inc. bought $28.8K2026-03-03 · Opaleye Management Inc. bought $28.8K2026-06-15 · Opaleye Management Inc. bought $27.3K2026-02-23 · Opaleye Management Inc. bought $24.6K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ACOG: institutional holders (13F)

13F holdings, latest reported quarter
Opaleye Management Inc.
2,895,467 sh
$20.9M
Solas Capital Management, LLC
1,924,617 sh
$13.9M
AWM Investment Company, Inc.
1,672,168 sh
$12.1M
Cable Car Capital, LP
1,382,339 sh
$10.0M
Ikarian Capital, LLC
836,259 sh
$6.0M

Congress trades in ACOG

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ACOG planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

ACOG mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Nasdaq Composite Index Fund
$74.2K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
1 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 4
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
3 insiders reported buying shares.
The record shows a net $6.2M bought by insiders over 180 days, 8 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ACOG financials

Net margin
-202.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$15.3M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Free cash flow, TTM
-$31.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.02x
long-term debt only, 2024-09-30 (21 months older than the period end); equity 2026-06-30
Cash flow to debt
-30.76x
TTM operating cash flow over long-term debt only, 2024-09-30 (21 months older than the period end)
Return on equity
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on assets
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on invested capital
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on capital employed
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$140.4M
market value at close 2026-10-26 on 2026-08-13 shares, plus long-term debt only, 2024-09-30 (21 months older than the period end), minus cash 2026-06-30
FCF yield
-17.2%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-12
Revenue$10.2Mn/an/a
Operating income-$22.7M-$12.0M-$9.9M
Net income-$20.7M-$14.8M-$13.8M
EPS (diluted)-1.18-2.04-3.84
Operating cash flow-$20.4M-$7.8M-$8.8M
Cash$66.0M$48.5M$1.4M
SEC XBRL, fiscal years, as known on 2026-10-27

ACOG Stock Sonar score 4/7 axes

Find similar shapesCompare

ACOG ranks highest on insider conviction (91st percentile) and risk and compliance (79th), and lowest on institutional and government (11th), among Pharma & Biotech peers.

Financial health
43
Inputs
  • Debt to equity0.02x · 72 pct, sector of 352
  • Cash flow to debt-30.76x · 15 pct, sector of 371
Insider conviction
91
Inputs
  • Net Form 4 buying (codes P and S), 180d$6.2M · 94 pct, sector of 428
  • Insider buyers, 180d3 · 89 pct, sector of 437
Institutional and government
11
Inputs
  • Funds adding, latest quarter8 · 11 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
79
Inputs
  • Short interest, % of float+3.0% · 68 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+3.4% · 91 pct, sector of 511
3 not measured: Profitability, Growth, US patents
  • Profitability needs 2 of 4 inputs, 0 present: the filed year and its quarters do not reconcile, so the trailing figure is withheld
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ACOG filings, in plain words

Are Alpha Cognition insiders buying or selling ACOG?

In the 180 days to 2026-10-27, Alpha Cognition insiders were net buyers, a net $6.2M across purchases and sales reported on Form 4, by 3 buyers.

Read the full summary

In the 180 days to 2026-10-27, Alpha Cognition insiders were net buyers of ACOG, a net $6.2M across purchases and sales reported on Form 4 by 3 buyers. Most of that figure, $6.1M, came from a holder of 10% or more rather than an officer or director. 2 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies